Element Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-18,615
Closed -$2.5M 28
2022
Q3
$2.5M Hold
18,615
1.2% 23
2022
Q2
$2.85M Buy
18,615
+6,205
+50% +$948K 1.43% 19
2022
Q1
$2.01M Buy
+12,410
New +$1.8M 1.01% 27
2020
Q3
Sell
-2,068
Closed -$203K 62
2020
Q2
$203K Buy
+2,068
New +$182K 0.06% 57
2019
Q4
Sell
-77,479
Closed -$5.87M 45
2019
Q3
$5.87M Buy
+77,479
New +$5.31M 0.51% 50
2019
Q2
Sell
-31,186
Closed -$2.51M 239
2019
Q1
$2.51M Sell
31,186
-2,043
-6% -$167K 0.08% 221
2018
Q4
$3.06M Buy
+33,229
New +$2.92M 0.09% 174
2018
Q3
Sell
-39,165
Closed -$3.63M 878
2018
Q2
$3.63M Buy
39,165
+21,060
+116% +$2.06M 0.1% 95
2018
Q1
$1.71M Buy
+18,105
New +$1.99M 0.04% 157
2016
Q3
Sell
-52,112
Closed -$3.23M 55
2016
Q2
$3.23M Buy
52,112
+9,591
+23% +$584K 0.49% 37
2016
Q1
$2.43M Buy
42,521
+10,324
+32% +$575K 0.36% 49
2015
Q4
$1.91M Sell
32,197
-751
-2% -$43.3K 0.37% 42
2015
Q3
$1.79M Buy
32,948
+23,648
+254% +$1.54M 0.65% 30
2015
Q2
$625K Buy
+9,300
New +$607K 0.22% 49

Other funds holding ABBV

Element Capital Management's ABBV Position: Q4 2022 in Review

Element Capital Management sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 18,615 shares — an estimated $2.5M sold.

Element Capital Management first reported a position in ABBV in Q2 2015 and held it in 14 quarters. The position peaked at $5.87M in Q3 2019. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Element Capital Management reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
  • Element Capital Management sold 18,615 AbbVie shares in Q4 2022, an estimated $2.5M.
  • Element Capital Management first reported a position in AbbVie in Q2 2015 and held it in 14 quarters.
  • Element Capital Management's AbbVie position peaked at $5.87M in Q3 2019.
  • 3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Element Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.